Phase 1 Clinical Trial to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of DWP212525 in Healthy Volunteers

Record History

1. Notable Jun 3, 2026 Primary completion date: Jun 30, 2026 to Dec 30, 2026 Primary endpoints: 6 to 4 · Enrollment target: 76 to 84 · Completion date: Jun 30, 2026 to Mar 30, 2027 · 5 morev3 Show 8 more changesShow less

   • Primary endpoints: 6 to 4
   • Enrollment target: 76 to 84
   • Completion date: Jun 30, 2026 to Mar 30, 2027
   • Interventions: DWP212525 100mg (Drug), DWP212525 10mg (Drug), DWP212525 200mg (Drug), DWP212525 30mg (Drug), DWP212525 400mg (Drug), DWP212525 50mg… to DWP212525 XXmg (Drug), DWP212525 placebo (Drug)
   • Study arms: 10 to 11
   • Eligibility criteria shortened, about 2 words
   • Study description shortened, about 1 word
   • Study title expanded, about 3 words

   See this version in full on ClinicalTrials.gov ↗

2. Minor Dec 15, 2024 Site contact updated Study title expanded, about 6 wordsv2 Show 1 more changeShow less

   • Study title expanded, about 6 words

   See this version in full on ClinicalTrials.gov ↗

3. Minor Dec 13, 2024 Study First Submitted

• Stopped: an ongoing trial was terminated, suspended or withdrawn.
• Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
• Minor: routine progress and housekeeping, such as sites added or enrollment closed.